Yao J, Battell M L, McNeill J H
Division of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada.
Can J Physiol Pharmacol. 1997 Feb;75(2):83-90.
Controversial reports on the efficacy and possible toxicity of vanadium obtained from various studies may be attributed to differences in the method of diabetes induction and (or) to differences in animal strains. The objective of this study was to evaluate the contribution of these two factors to the effects of vanadium in the treatment of experimental diabetes. Two methods of streptozotocin induction of diabetes in rats have been used for studying the antidiabetic effects of vanadium. One involves a single intravenous injection of 60 mg/kg streptozotocin, and the other uses two subcutaneous injections of 40 mg/kg streptozotocin, to either Wistar or Sprague-Dawley rats. In a 7-week chronic study, Sprague-Dawley rats appeared to develop a more severe diabetes (indicated by higher plasma cholesterol and higher fasting plasma glucose levels) following the single intravenous injection of streptozotocin than rats made diabetic by two subcutaneous injections of streptozotocin. Irrespective of the method of diabetes induction, the responses of all the diabetic animals to chronic vanadyl sulphate treatment were similar. In an acute study, Wistar diabetic rats were more responsive than Sprague-Dawley diabetic rats to vanadyl sulphate and to lower doses (0.6 and 0.8 mmol/kg) of a new organic vanadium compound, bis(maltolato)oxovanadium(i.v.).
从各项研究中得出的关于钒的功效及可能存在的毒性的有争议报告，可能归因于糖尿病诱导方法的差异和（或）动物品系的差异。本研究的目的是评估这两个因素对钒治疗实验性糖尿病效果的影响。已采用两种链脲佐菌素诱导大鼠糖尿病的方法来研究钒的抗糖尿病作用。一种方法是单次静脉注射60毫克/千克链脲佐菌素，另一种方法是对Wistar或Sprague-Dawley大鼠进行两次皮下注射40毫克/千克链脲佐菌素。在一项为期7周的慢性研究中，单次静脉注射链脲佐菌素后，Sprague-Dawley大鼠似乎比两次皮下注射链脲佐菌素诱导糖尿病的大鼠发展出更严重的糖尿病（表现为血浆胆固醇水平更高和空腹血糖水平更高）。无论糖尿病诱导方法如何，所有糖尿病动物对慢性硫酸氧钒治疗的反应都是相似的。在一项急性研究中，Wistar糖尿病大鼠比Sprague-Dawley糖尿病大鼠对硫酸氧钒和较低剂量（0.6和0.8毫摩尔/千克）的新型有机钒化合物双（麦芽醇根）氧钒（静脉注射）反应更敏感。
